Literature DB >> 27557390

Epidemiological overview, advances in diagnosis, prevention, treatment and management of epithelial ovarian cancer in Mexico.

Dolores Gallardo-Rincón, Raquel Espinosa-Romero, Wendy Rosemary Muñoz, Roberto Mendoza-Martínez, Susana Del Villar-Álvarez, Luis Oñate-Ocaña, David Isla-Ortiz, Juan Pablo Márquez-Manríquez, Ángel Apodaca-Cruz, Abelardo Meneses-García.   

Abstract

The epithelial ovarian cancer (EOC) has been underdiagnosed because it does not have a specific clinical presentation, and the signs and symptoms are similar to the irritable bowel syndrome and pelvic inflammatory disease. EOC is less common than breast and cervical cancer, but it is more lethal. On the whole, EOC has an early dissemination to peritoneal cavity, which delays a timely diagnosis and increases the rate of advanced diagnosed disease. The diagnosis usually surprises the women and the primary care physician. Therefore, it is necessary to count on prevention and early diagnosis programs. EOC has 80% response to surgical treatment, but nearly 70% of the patients may relapse in five years. The objectives of this document are presenting a summary of the EOC epidemiology and comment about advancements in prevention, diagnosis, and treatment of this cancer. That will raise awareness about the importance of this disease.

Entities:  

Mesh:

Year:  2016        PMID: 27557390     DOI: 10.21149/spm.v58i2.7801

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  2 in total

1.  Activation of the LKB1‑SIK1 signaling pathway inhibits the TGF‑β‑mediated epithelial‑mesenchymal transition and apoptosis resistance of ovarian carcinoma cells.

Authors:  Bo Hong; Jianmei Zhang; Wenlan Yang
Journal:  Mol Med Rep       Date:  2017-12-08       Impact factor: 2.952

2.  Celastrol Loaded Nanoparticles With ROS-Response and ROS-Inducer for the Treatment of Ovarian Cancer.

Authors:  Weina Niu; Jianguo Wang; Qinyao Wang; Jianjun Shen
Journal:  Front Chem       Date:  2020-10-30       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.